読み込み中
Arrowhead Pharmaceuticals, Inc., founded in 1989 and based in Pasadena, California, is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for complex and challenging-to-treat diseases within the United States. The company's extensive therapeutic pipeline primarily leverages RNA interference (RNAi) technology. Among its advanced clinical programs are: ARO-AAT, a Phase II therapeutic targeting liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is undergoing both Phase 2b and Phase 3 clinical evaluations for hypertriglyceridemia; ARO-ANG3, currently in Phase 2b development to reduce the production of angiopoietin-like protein 3; and ARO-HIF2, a Phase 1b candidate designed to treat clear cell renal cell carcinoma. Arrowhead also has several compounds in earlier clinical development, including ARO-HSD in Phase 1/2a for other liver diseases, ARO-ENaC in Phase 1/2a, aimed at decreasing the epithelial sodium channel alpha subunit in lung airways, and ARO-C3, also in Phase 1/2a, for complement-mediated diseases. Further expanding its diverse portfolio, the company is actively developing ARO-Lung2 for chronic obstructive pulmonary disorder (COPD), ARO-DUX4 for facioscapulohumeral muscular dystrophy, ARO-XDH for uncontrolled gout, and ARO-COV for COVID-19 and other pulmonary-borne pathogens. Beyond its core internal programs, Arrowhead is involved in the progression of JNJ-3989, a subcutaneously administered RNAi therapeutic for chronic hepatitis B virus infection; Olpasiran, intended to reduce apolipoprotein A production; and ARO-AMG1, which targets genetically validated cardiovascular pathways. Strategic collaborations are integral to Arrowhead's development efforts. The company holds a licensing and research agreement with Janssen Pharmaceuticals, Inc. for the co-development of ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3, all RNAi therapeutics focused on liver-expressed targets. Additionally, Arrowhead has a licensing and research partnership with Takeda Pharmaceuticals U.S.A., Inc. to develop an RNAi therapeutic candidate specifically for liver disease.
前日終値
$62.75
+$2.01 · +3.31%
日中の時刻はETです。市場データは遅延する場合があります。
Arrowhead Pharmaceuticals, Inc., founded in 1989 and based in Pasadena, California, is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for complex and challenging-to-treat diseases within the United States. The company's extensive therapeutic pipeline primarily leverages RNA interference (RNAi) technology. Among its advanced clinical programs are: ARO-AAT, a Phase II therapeutic targeting liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is undergoing both Phase 2b and Phase 3 clinical evaluations for hypertriglyceridemia; ARO-ANG3, currently in Phase 2b development to reduce the production of angiopoietin-like protein 3; and ARO-HIF2, a Phase 1b candidate designed to treat clear cell renal cell carcinoma. Arrowhead also has several compounds in earlier clinical development, including ARO-HSD in Phase 1/2a for other liver diseases, ARO-ENaC in Phase 1/2a, aimed at decreasing the epithelial sodium channel alpha subunit in lung airways, and ARO-C3, also in Phase 1/2a, for complement-mediated diseases. Further expanding its diverse portfolio, the company is actively developing ARO-Lung2 for chronic obstructive pulmonary disorder (COPD), ARO-DUX4 for facioscapulohumeral muscular dystrophy, ARO-XDH for uncontrolled gout, and ARO-COV for COVID-19 and other pulmonary-borne pathogens. Beyond its core internal programs, Arrowhead is involved in the progression of JNJ-3989, a subcutaneously administered RNAi therapeutic for chronic hepatitis B virus infection; Olpasiran, intended to reduce apolipoprotein A production; and ARO-AMG1, which targets genetically validated cardiovascular pathways. Strategic collaborations are integral to Arrowhead's development efforts. The company holds a licensing and research agreement with Janssen Pharmaceuticals, Inc. for the co-development of ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3, all RNAi therapeutics focused on liver-expressed targets. Additionally, Arrowhead has a licensing and research partnership with Takeda Pharmaceuticals U.S.A., Inc. to develop an RNAi therapeutic candidate specifically for liver disease.
日中レンジ
現在 $62.75
52週レンジ
現在 $62.75
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
71
割安
センチメント
47
まちまち
リスク
44
やや高いリスク
モメンタム
68
上昇基調
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Arrowhead Pharmaceuticals, Inc., founded in 1989 and based in Pasadena, California, is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for complex and challenging-to-treat diseases within the United States. The company's extensive therapeutic pipeline primarily leverages RNA interference (RNAi) technology. Among its advanced clinical programs are: ARO-AAT, a Phase II therapeutic targeting liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is undergoing both Phase 2b and Phase 3 clinical evaluations for hypertriglyceridemia; ARO-ANG3, currently in Phase 2b development to reduce the production of angiopoietin-like protein 3; and ARO-HIF2, a Phase 1b candidate designed to treat clear cell renal cell carcinoma. Arrowhead also has several compounds in earlier clinical development, including ARO-HSD in Phase 1/2a for other liver diseases, ARO-ENaC in Phase 1/2a, aimed at decreasing the epithelial sodium channel alpha subunit in lung airways, and ARO-C3, also in Phase 1/2a, for complement-mediated diseases. Further expanding its diverse portfolio, the company is actively developing ARO-Lung2 for chronic obstructive pulmonary disorder (COPD), ARO-DUX4 for facioscapulohumeral muscular dystrophy, ARO-XDH for uncontrolled gout, and ARO-COV for COVID-19 and other pulmonary-borne pathogens. Beyond its core internal programs, Arrowhead is involved in the progression of JNJ-3989, a subcutaneously administered RNAi therapeutic for chronic hepatitis B virus infection; Olpasiran, intended to reduce apolipoprotein A production; and ARO-AMG1, which targets genetically validated cardiovascular pathways. Strategic collaborations are integral to Arrowhead's development efforts. The company holds a licensing and research agreement with Janssen Pharmaceuticals, Inc. for the co-development of ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3, all RNAi therapeutics focused on liver-expressed targets. Additionally, Arrowhead has a licensing and research partnership with Takeda Pharmaceuticals U.S.A., Inc. to develop an RNAi therapeutic candidate specifically for liver disease.
日中レンジ
現在 $62.75
52週レンジ
現在 $62.75
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 8.29億 USD | 355.1万 USD | 2.41億 USD | 2.43億 USD | 1.38億 USD |
| 売上原価 | — | 1859.5万 USD | 1249.3万 USD | 1042.1万 USD | — |
| 粗利益 | 8.29億 USD | −1504.4万 USD | 2.28億 USD | 2.33億 USD | 1.38億 USD |
| 研究開発 | 6.07億 USD | 4.89億 USD | 3.42億 USD | 2.89億 USD | 2.06億 USD |
| 販売・一般管理 | 1.22億 USD | 9682万 USD | 9093.2万 USD | 1.24億 USD | 8098.1万 USD |
| 営業費用 | 7.31億 USD | 5.86億 USD | 4.33億 USD | 4.11億 USD | 2.87億 USD |
| 受取利息 | 3728.9万 USD | 2272万 USD | 1529.9万 USD | 503.3万 USD | 612万 USD |
| 支払利息 | 8936.1万 USD | 3235.2万 USD | 1832.6万 USD | — | — |
| 減価償却費と償却費 | 2392.8万 USD | 1859.5万 USD | 1249.3万 USD | 1042.1万 USD | 826.7万 USD |
| 営業利益 | 9834.6万 USD | −6.01億 USD | −2.05億 USD | −1.79億 USD | −1.49億 USD |
| 純利益 | −163.1万 USD | −5.99億 USD | −2.05億 USD | −1.76億 USD | −1.41億 USD |
会社概要が更新されました 2026年10月11日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$100.63
上昇余地（60.37%）| 種別 | 発効日 | 詳細 | 基準日 | 支払日 |
|---|---|---|---|---|
株式分割 | 2011年11月17日 | 1:10 | — | — |
株式分割 | 2004年1月15日 | 1:65 | — | — |
発効済み 2011年11月17日
1:10
発効済み 2004年1月15日
1:65
この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI3.51億0.01%2.3兆 USD0.03%$381.94+0.63%
Vanguard Morningstar Small-Cap ETFVB2.54億0.14%1853億 USD0.03%$289.48+0.64%
Vanguard Morningstar Small-Cap Growth ETFVBK1.46億0.32%447億 USD0.05%$344.74+1.22%
Vanguard Extended Market ETFVXF1.35億0.14%954億 USD0.05%$235+0.80%
Invesco S&P MidCap Momentum ETFXMMO1.14億1.59%71.38億 USD0.34%$148.79+0.96%
State Street SPDR S&P Biotech ETFXBI1.1億1.11%98.74億 USD0.35%$153.77+3.00%
State Street SPDR S&P MIDCAP 400 ETF TrustMDY6374.35万0.25%258.17億 USD0.23%$669.87+0.54%
iShares Biotechnology ETFIBB6258.56万0.59%108.2億 USD0.44%$206.49+3.00%Vanguard Morningstar Total Stock Market ETFVTIVanguard Morningstar Small-Cap ETFVBVanguard Morningstar Small-Cap Growth ETFVBKVanguard Extended Market ETFVXFInvesco S&P MidCap Momentum ETFXMMOState Street SPDR S&P Biotech ETFXBIState Street SPDR S&P MIDCAP 400 ETF TrustMDYiShares Biotechnology ETFIBBAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
